142 related articles for article (PubMed ID: 20851657)
1. Serious herpes zoster in rheumatoid arthritis under anti-interleukin-6 receptor antibody.
Kubandova Z; Mathieu S; Pourtier C; Soubrier M
Joint Bone Spine; 2010 Dec; 77(6):623-4. PubMed ID: 20851657
[No Abstract] [Full Text] [Related]
2. Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-alpha agents.
Strangfeld A; Listing J; Herzer P; Liebhaber A; Rockwitz K; Richter C; Zink A
JAMA; 2009 Feb; 301(7):737-44. PubMed ID: 19224750
[TBL] [Abstract][Full Text] [Related]
3. Herpes zoster in patients taking TNFalpha antagonists for chronic inflammatory joint disease.
Wendling D; Streit G; Toussirot E; Prati C
Joint Bone Spine; 2008 Oct; 75(5):540-3. PubMed ID: 18674945
[TBL] [Abstract][Full Text] [Related]
4. Exacerbation of chronic active Epstein-Barr virus infection in a patient with rheumatoid arthritis receiving humanised anti-interleukin-6 receptor monoclonal antibody.
Ogawa J; Harigai M; Akashi T; Nagasaka K; Suzuki F; Tominaga S; Miyasaka N
Ann Rheum Dis; 2006 Dec; 65(12):1667-9. PubMed ID: 17105857
[No Abstract] [Full Text] [Related]
5. [New approaches to pharmacotherapy for rheumatoid arthritis: perspective for use of tocilizumab (monoclonal antibodies to interleukin-6 receptor)].
Nasonov EL
Ter Arkh; 2010; 82(5):64-71. PubMed ID: 20597275
[TBL] [Abstract][Full Text] [Related]
6. Inhibiting interleukin-6 in rheumatoid arthritis.
Choy E
Curr Rheumatol Rep; 2008 Oct; 10(5):413-7. PubMed ID: 18817647
[TBL] [Abstract][Full Text] [Related]
7. [Therapeutic efficacy and the adverse effects of newly developed biological agents for rheumatoid arthritis].
Kondo H
Nihon Naika Gakkai Zasshi; 2004 Jan; 93(1):153-60. PubMed ID: 14968591
[No Abstract] [Full Text] [Related]
8. Development of varicella during adalimumab therapy.
Lee DH; Kim HS; Song YW; Cho KH
J Eur Acad Dermatol Venereol; 2007 May; 21(5):687-8. PubMed ID: 17447988
[No Abstract] [Full Text] [Related]
9. Therapy: The risk of herpes zoster: another cost of anti-TNF therapy?
Bongartz T; Orenstein R
Nat Rev Rheumatol; 2009 Jul; 5(7):361-3. PubMed ID: 19568250
[No Abstract] [Full Text] [Related]
10. Herpes zoster in the age of focused immunosuppressive therapy.
Whitley RJ; Gnann JW
JAMA; 2009 Feb; 301(7):774-5. PubMed ID: 19224757
[No Abstract] [Full Text] [Related]
11. Interleukin-6: a new therapeutic target.
Smolen JS; Maini RN
Arthritis Res Ther; 2006; 8 Suppl 2(Suppl 2):S5. PubMed ID: 16899109
[TBL] [Abstract][Full Text] [Related]
12. Interleukin 6 receptor as a target for the treatment of rheumatoid arthritis.
Choy E
Ann Rheum Dis; 2003 Nov; 62 Suppl 2(Suppl 2):ii68-9. PubMed ID: 14532153
[No Abstract] [Full Text] [Related]
13. Interleukin-6 inhibition for treatment of rheumatoid arthritis: a review of tocilizumab therapy.
Patel AM; Moreland LW
Drug Des Devel Ther; 2010 Oct; 4():263-78. PubMed ID: 21116333
[TBL] [Abstract][Full Text] [Related]
14. Immediate reduction of white blood cell count after tocilizumab administration was observed in some cases.
Nagamine R; Chen W; Hara T; Kondo K; Sugioka Y
Mod Rheumatol; 2009; 19(3):348-50. PubMed ID: 19288171
[No Abstract] [Full Text] [Related]
15. Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study.
Genovese MC; McKay JD; Nasonov EL; Mysler EF; da Silva NA; Alecock E; Woodworth T; Gomez-Reino JJ
Arthritis Rheum; 2008 Oct; 58(10):2968-80. PubMed ID: 18821691
[TBL] [Abstract][Full Text] [Related]
16. Interleukin-6 inhibition--tolerability profile and clinical implications.
Strand V; Yazici Y
Bull NYU Hosp Jt Dis; 2007; 65 Suppl 1():S21-4. PubMed ID: 17708741
[TBL] [Abstract][Full Text] [Related]
17. Improvement of HbA1c during treatment with humanised anti-interleukin 6 receptor antibody, tocilizumab.
Ogata A; Morishima A; Hirano T; Hishitani Y; Hagihara K; Shima Y; Narazaki M; Tanaka T
Ann Rheum Dis; 2011 Jun; 70(6):1164-5. PubMed ID: 20980285
[No Abstract] [Full Text] [Related]
18. Successful treatment of reactive arthritis with a humanized anti-interleukin-6 receptor antibody, tocilizumab.
Tanaka T; Kuwahara Y; Shima Y; Hirano T; Kawai M; Ogawa M; Arimitsu J; Hagihara K; Narazaki M; Ogata A; Kawase I; Kishimoto T
Arthritis Rheum; 2009 Dec; 61(12):1762-4. PubMed ID: 19950316
[No Abstract] [Full Text] [Related]
19. New drugs for rheumatoid arthritis.
Olsen NJ; Stein CM
N Engl J Med; 2004 May; 350(21):2167-79. PubMed ID: 15152062
[No Abstract] [Full Text] [Related]
20. [Biological agents for therapy of rheumatoid arthritis--overview].
Takeuchi T
Nihon Rinsho; 2005 Jan; 63 Suppl 1():513-6. PubMed ID: 15799409
[No Abstract] [Full Text] [Related]
[Next] [New Search]
